Review Article

Mesenchymal Stem Cells and Cutaneous Wound Healing: Current Evidence and Future Potential

M. Isakson,1 C. de Blacam,1 D. Whelan,2 A. McArdle,1 and A. J. P. Clover1,2

1Department of Plastic and Reconstructive Surgery, Cork University Hospital, Cork, Ireland
2Centre for Research in Vascular Biology, University College Cork, Cork, Ireland

Correspondence should be addressed to A. J. P. Clover; j.clover@ucc.ie

Received 13 February 2015; Accepted 7 May 2015

Academic Editor: Susan Liao

Copyright © 2015 M. Isakson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human skin is a remarkable organ that sustains insult and injury throughout life. The ability of skin to expeditiously repair wounds is paramount to survival. With an aging global population, coupled with a rise in the prevalence of conditions such as diabetes, chronic wounds represent a significant biomedical burden. Mesenchymal stem cells (MSC), a progenitor cell population of the mesoderm lineage, have been shown to be significant mediators in inflammatory environments. Preclinical studies of MSC in various animal wound healing models point towards a putative therapy. This review examines the body of evidence suggesting that MSC accelerate wound healing in both clinical and preclinical studies and also the possible mechanisms controlling its efficacy. The delivery of a cellular therapy to the masses presents many challenges from a safety, ethical, and regulatory point of view. Some of the issues surrounding the introduction of MSC as a medicinal product are also delineated in this review.

1. Introduction

Chronic wounds occur when there is a failure of injured skin to proceed through an orderly and timely process to produce anatomic and functional integrity. Causative factors include malnutrition and immunosuppression, and chronic wounds are commonly seen as a consequence of diabetes mellitus and vascular compromise. Current techniques to manage chronic wounds typically focus on modification of controllable causative factors: antibiotic treatment of infected wounds, pressure relief of decubitus areas, revascularization of ischemic limbs, and compression garments for venous insufficiency [6, 7]. Surgical debridement and negative pressure wound therapy are commonly employed techniques but remain a suboptimal treatment due to the lengthy healing time required for this method. The advent of skin substitutes has increased our armamentarium for treating this difficult condition, but to date no ideal therapy is available to treat troublesome, chronic wounds. Despite huge advances in medical care and nutrition which have resulted in a commendable change in the outcome of chronic wound management, new therapies in this area are required to optimize outcomes for our patients. Stem cells, with their unique properties to self-renew and undergo differentiation, are emerging...
as a promising candidate for cell-based therapy for the treatment of chronic wounds.

The term “stem cell” refers to a myriad of different cell types that share two key characteristics: self-renewal and the potential for differentiation into different cell types. Adult stem cells are not limited to the same extent by low availability and ethical concerns that limit the use of embryonic stem cells, thus making them an ideal cell type for tissue regeneration applications. Of the numerous types of adult stem cells that have been described in the literature, two types are of particular relevance to tissue engineering in the setting of chronic wounds: bone-marrow-derived mesenchymal stem cells (BM-MSCs) and adipose-derived stromal cells (ASCs). Bone marrow was the first source that was reported to contain MSCs [8]. However, the isolation of these cells is fraught with considerable donor site morbidity and low cell yield. ASCs represent a similar cell type of multilineage potential. They are isolated from the stromal vascular fraction of adipose tissue after a digestion and centrifugation step [9]. In 2001, Zuk et al. demonstrated that human fat obtained from human lipoaspirates contained multilineage stem cells, which have since been shown to have the potential to undergo adipogenesis, osteogenesis, chondrogenesis, and myogenesis in vitro and in vivo [10–14] (Figure 1).

Stem cells offer enormous potential for enhancing tissue repair and regeneration following injury. The rapidly developing fields of stem cell biology and skin tissue engineering have created translational opportunities for the development of novel stem cell-based wound healing therapies that show promising results in preclinical and clinical trials for the treatment of chronic wounds. In this review, we evaluate the current evidence for adult stem cell-based therapies and their application to chronic wound healing.

2. Methods

2.1. Data Sources and Searches. The topic “mesenchymal stem cells” AND “cutaneous wound healing” was explored to determine significant issues (conceptual mapping). From this, a search strategy was devised using the following key terms: (mesenchymal stem cells OR MSC OR stromal OR adipose derived) AND (cutaneous wound healing OR wound repair OR burn). Using these key terms, an electronic bibliographic search was conducted in MEDLINE and CENTRAL (The Cochrane Central Register of Controlled Trials) from inception until November 31, 2012. Limits were placed on each search to exclude non-English citations. Reference lists of all relevant publications were searched for additional papers. Hand searching of key journals was undertaken and relevant conference proceedings were also examined.

2.2. Study Selection. Inclusion and exclusion criteria for selection are listed in Table 1. A staged review of article titles and abstracts was performed to select all studies that met the inclusion criteria. Studies whose abstracts met the inclusion criteria were retrieved and the full text was analyzed. Papers, using animal models, selected for full text review are listed in Table 2.

2.3. Data Extraction, Synthesis, and Analysis. Data extraction and quality assessment were performed, with the following variables being recorded from each study: cell source, characterization technique, recipient, injury model, cell delivery technique, and wound healing outcome. The papers included in our final analysis were heterogeneous in their methodology and results, thus precluding a formal pooled analysis.
Table 1: Exclusion/inclusion criteria.

| Inclusion criteria                                                                 | Exclusion criteria                                      |
|-------------------------------------------------------------------------------------|----------------------------------------------------------|
| (1) Original scientific studies                                                    | (1) Review articles                                      |
| (2) Studies investigating mesenchymal stem cells in vivo                            | (2) In vitro studies                                     |
| (3) Studies involving cells derived from bone marrow or adipose tissue              | (3) Studies involving noncutaneous models                |
| (4) Studies involving cutaneous wounds or burns                                      | (4) Studies involving radiation injury models             |

(Figure 2). Therefore, a narrative summary of results was undertaken.

3. Results and Discussion

MSCs are nonhematopoietic stromal cells capable of multilineage differentiation that show enormous potential for clinical translation for the treatment of chronic wounds. Adult MSCs have been isolated from various sites, including bone marrow, adipose tissue, and amniotic fluid. Use of adult MSCs provides an easily accessible source of multipotent precursor cells that could potentially avoid the ethical concerns associated with other stem cell types, particularly embryonic stem cells. Additionally, transplantation with postnatal stem cells bypasses the possibility of immune rejection that could occur with other cell types [65].

ASCs and BM-MSCs share many common characteristics, including multilineage differentiation potential (Figure 1), morphology, telomerase activity, and gene expression [14]. In addition, they share a similar cell surface marker phenotype; however, a definitive profile that allows for the prospective isolation of MSCs has not been firmly established. In general, ASCs are considered to be CD45−CD235a−CD31−CD34+ with the addition of positivity for CD106 and CD36 distinguishing them from BM-MSCs [66, 67]; however, we found a variety of cell surface markers used to define these cells in the papers we examined.

3.1. Cutaneous Wound Models and Cell Processing Technique

Rodent models were used in 78% of the papers assessed, with incisional, excisional, and burn wounds used to assess healing (Figure 3). The majority of studies measured healing based on gross examination of wound area. Rodents are typically used as animal models for preclinical wound healing studies. Rodents are attractive candidates for wound healing studies because of their availability, low cost, and ease of handling. However, rodent models have been criticized because the major mechanism of wound closure is contraction, whereas in humans reepithelialization and granulation tissue formation are the major mechanisms involved [68]. The advent of a novel wound splinting model, utilizing a silicone splint in rodents, has allowed for an accurate, reproducible model of wound healing that facilitates "humanized" wound healing through the processes of granulation and reepithelialization [68].

Thirty-five articles were identified that harvested BM-MSCs and 22 that used ASCs. One of the drawbacks to direct comparison between papers was the lack of uniform cell isolation and delivery methods used in the studies. In terms of cell isolation, studies employed various techniques using either freshly isolated cells, with or without prospective isolation for subpopulations using flow cytometry, or periods of in vitro expansion. The lack of a standard cell profile phenotype and standard cell isolation protocol is one of the major limitations that is hindering translation of adult stem cell
| Author                  | Cell source | Wound model      | Cell delivery method         | Cell number    | Mechanism of action                                                                 |
|-------------------------|-------------|------------------|------------------------------|----------------|-------------------------------------------------------------------------------------|
| Altman et al. [15]      | Human       | Excisional       | Seeded matrix                | $1 \times 10^7$ seeded twice | Local engraftment with endothelial and fibroblastic phenotype                          |
| Altman et al. [16]      | Human       | Excisional       | Silk fibrin chitosan scaffold | $1 \times 10^5$ | N/A                                                                                  |
| Angóko Neto et al. [17] | Mouse       | Excisional       | Unclear                      |                | $\uparrow$ collagen types I & III                                                   |
| Blanton et al. [18]     | Pig         | Excisional       | Fibrin spray matrix          | $18 \times 10^5$ | $\downarrow$ inflammation, $\uparrow$ neovascularization, $\uparrow$ fibroblast number, $\uparrow$ collagen thickness |
| Chen et al. [20]        | Mouse       | Excisional       | Intradermal and topical      | $1 \times 10^7$ | Engraftment of macrophages and progenitor cells (CD34, c-kit, Flk-1)                |
| Chen et al. [21]        | Mouse       | Excisional       | Intradermal and topical      | N/A            | Enlarged histology score at d7, d14                                                |
| Cho et al. [22]         | Human (CM)  | Excisional       | Intradermal                  | N/A            | $\downarrow$ inflammation, $\uparrow$ angiogenesis, $\uparrow$ collagen content, $\uparrow$ VEGF |
| Ebrahimian et al. [23]  | Not specified | Excisional       | IV and IM                    | $1 \times 10^6$ | Engraftment of MSCs at d18                                                          |
| Falanga et al. [24]     | Mouse       | Excisional       | Topical fibrin scaffold      | $1 \times 10^7$/cm² | $\uparrow$ capillary density                                                        |
| Fu et al. [25]          | Pig         | Burn             | Fibrin mesh scaffold +/- cytokines | $2 \times 10^6$ | $\uparrow$ capillary density, perivascular engraftment, $\uparrow$ VEGF, HIF-α expression |
| Ge et al. [26]          | Pig         | Excisional       | Topical                      | N/A            | $\uparrow$ vascularity and cellularity in treatment groups                           |
| Gao et al. [27]         | Human (CM)  | Ischemic flap    | Local                        | N/A            | Cell engraftment in epidermis, hair follicles, sebaceous glands and dermis, blood vessels |
| Gu et al. [28]          | Human       | Excisional       | Intradermal                  | $1 \times 10^7$ | No differences in total blood vessel number                                          |
| Hamou et al. [29]       | Mouse       | Ischemic flap    | Intradermal                  | $0.6 \times 10^4$ | $\uparrow$ fibroblast numbers                                                       |
| Heo et al. [30]         | Human (CM)  | Excisional       | Topical +/- TNF-a            | N/A            | $\uparrow$ epithelialization, $\uparrow$ granulation tissue thickness, $\uparrow$ capillary number, $\uparrow$ VEGF, $\uparrow$ bFGF |
| Hou et al. [31]         | Human       | Excisional       | Collagen                     | $2 \times 10^4$ | $\uparrow$ neovascularization, $\uparrow$ collagen production, $\uparrow$ expression of VEGF, EGF, PDGF-B, TGF-B |
| Huang et al. [32]       | Human       | Excisional       | Topical microsphere scaffold | $1 \times 10^6$ | $\uparrow$ epithelialization and enhanced granulation tissue formation              |
| Javazon et al. [33]     | Mouse       | Excisional       | Topical                      | $7.5 \times 10^6$ | $\uparrow$ neovascularization                                                        |
| Kataoka et al. [34]     | Mouse       | Excisional       | SC                           | $5 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Kim et al. [35]         | Rat         | Excisional       | Collagen scaffold            | $2 \times 10^6$ | $\uparrow$ epithelialization, perivascular engraftment, VEGF, HIF-α expression      |
| Kim et al. [36]         | Human       | Excisional       | Collagen scaffold            | $1 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Kim et al. [37]         | Canine      | Excisional       | Intradermal +/- low level laser therapy | $1 \times 10^6$ | $\uparrow$ epithelialization, $\uparrow$ granulation tissue thickness, $\uparrow$ capillary number, $\uparrow$ neovascularization, $\uparrow$ collagen production, $\uparrow$ expression of VEGF, EGF, PDGF-B, TGF-B |
| Liao et al. [38]        | Rat         | Intradermal      | IV or intradermal            | N/A            | $\uparrow$ epithelialization                                                       |
| Lee et al. [39]         | Mouse       | Intradermal      | Collagen                     | $5 \times 10^4$ | $\uparrow$ epithelialization                                                       |
| Lee et al. [40]         | Human       | Intradermal      | Collagen                     | N/A            | $\uparrow$ epithelialization                                                       |
| Lee et al. [41]         | Human       | Intradermal      | Collagen gel                 | N/A            | $\uparrow$ epithelialization                                                       |
| Li et al. [42]          | Rat         | Intradermal      | IV                           | N/A            | $\uparrow$ epithelialization                                                       |
| Lim and Yoo [43]        | Mouse       | Excisional       | Intradermal                  | $0.6 \times 10^4$ | $\uparrow$ blood vessel density                                                    |
| Lin et al. [44]         | Human       | Excisional       | Cell sheet (1 or 3 layers)   | $1 \times 10^6$/layer | $\uparrow$ epithelialization, keratinization                                        |
| Liu et al. [45]         | Pig         | Burn             | Topical (scaffold)           | $2 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Liu et al. [46]         | Mouse       | Excisional       | Scaffold matrix              | $1 \times 10^5$ seeded twice | $\uparrow$ epithelialization, $\uparrow$ granulation, $\uparrow$ neovascularization |
| Maharlooee et al. [47]  | Rat         | Excisional       | Intradermal                  | $1 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Mansilla et al. [48]    | Rabbit      | Burn             | Fibrin mesh scaffold         | $2 \times 10^6$/mL/cm² | Heavy mononuclear infiltrate                                                        |
| McFarlin et al. [49]    | Rat         | Intradermal      | IV or SC                     | $6 \times 10^6$ | $\uparrow$ granulation, $\uparrow$ inflammation                                    |
| Nakagawa et al. [50]    | Human       | Excisional       | Collagen scaffold            | $5 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Nambu et al. [51]       | Mouse       | Excisional       | Seeded atelocollagen matrix  | $5 \times 10^7$ | $\uparrow$ epithelialization                                                       |
| Nambu et al. [52]       | Rat         | Excisional       | Seeded atelocollagen matrix  | $1 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Nie et al. [53]         | Rat         | Excisional       | Intradermal                  | $1 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Rasulov et al. [54]     | Rat         | Burn             | Topical                      | $2 \times 10^3$ | $\uparrow$ granulation, $\uparrow$ collagen production                             |
| Rustad et al. [55]      | Mouse       | Excisional       | Collagen hydrogel topical or SC | $2.5 \times 10^7$ | $\uparrow$ epithelialization                                                       |
| Sasaki et al. [56]      | Mouse       | Excisional       | IV                           | $1 \times 10^6$ | $\uparrow$ epithelialization, $\uparrow$ granulation tissue, $\uparrow$ histology scores |
| Sheng et al. [57]       | Human       | Burn             | SC or ADM                    | $1 \times 10^6$ | $\uparrow$ epithelialization, $\uparrow$ granulation tissue, $\uparrow$ histology scores |
| Shumakov et al. [58]    | Rat         | Burn             | Topical                      | $2 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Stoff et al. [59]       | Human       | Intradermal      | Collagen gel                 | N/A            | $\uparrow$ epithelialization                                                       |
| Tian et al. [60]        | Mouse       | Excisional       | Intradermal and topical      | $1 \times 10^6$ | $\uparrow$ epithelialization, $\uparrow$ granulation tissue, $\uparrow$ histology scores |
| Volk et al. [61]        | Rabbit      | Ischemic.        | SC                           | $0.5 \times 10^6$ | $\uparrow$ epithelialization                                                       |
| Wu et al. [62]          | Mouse       | Excisional       | Intradermal and topical      | $1 \times 10^6$ | $\uparrow$ epithelialization, $\uparrow$ granulation tissue, $\uparrow$ histology scores |
| Yang et al. [63]        | Rat         | Ischemic fl      | SC                           | $4 \times 10^6$ | $\uparrow$ epithelialization, $\uparrow$ granulation tissue, $\uparrow$ histology scores |
| Yeum et al. [64]        | Mouse       | Excisional       | Scaffold (small intestinal submuocosa) | $1 \times 10^6$ | $\uparrow$ epithelialization, $\uparrow$ granulation tissue, $\uparrow$ histology scores |
therapies. Of note, adult stem cells represent a heterogeneous cell population and interestingly subpopulations within these compartments are absent in certain conditions, such as diabetes, in which functional stem cells are required to adequately treat conditions [69, 70]. Additionally, it is important to note that cell surface phenotype can undergo significant phenotypic drift following a period of in vitro culture expansion and thus alter the ability to prospectively isolate multipotent subpopulations, perhaps altering their differentiation potential of cells in vivo [71]. Therefore, it is important that standardized protocols are developed to allow for clinical translation of these studies.

In addition to variations in cell isolation techniques, cell delivery methods for adult stem cells are also nonstandardized in the literature. Both topical and systemic delivery methods have been shown to be effective. For the purposes of this review, we considered topical, intradermal, and subcutaneous delivery as "local" and intramuscular, parabiotic, and intravenous delivery as "systemic" (Table 2). Local application with syringe-spray systems is the approach being utilized in current clinical trials [72, 73]. It is important to know that the choice of biomimetic scaffold plays a pivotal role in driving appropriate tissue regeneration in vivo. Since the extracellular matrix (ECM) plays a key role in guiding various biological processes, creating a scaffold that mimics the normal ECM should enhance tissue regeneration. As a result, advances in bioengineering have resulted in a myriad of cell delivery mechanisms and various scaffolds that again make comparison between methods difficult [55, 74, 75]. The local environment, including neighboring cells, soluble signaling molecules, ECM, mechanical forces, oxygen tension, and other factors, is crucial to enable stem cells to maintain their regenerative potential [76]. Ongoing research continues to identify novel techniques to deliver cellular therapeutics to specific locations in order to enhance cell survival and function, in what is typically a hostile wound environment [77, 78].

3.2. Wound Healing Results. All of the articles included in this study evaluated time to healing using adult stem cells in wound healing. All studies demonstrated accelerated wound closure and enhanced histological parameters in wounds treated with MSC therapies, irrespective of cell isolation or delivery method.

Despite a lack of a standardized histological scale for evaluating cutaneous wound healing, collagen deposition, neovascularization, and cellular infiltration are considered representative features. All studies that reported histological findings identified enhanced wound healing in wounds treated with MSCs compared to control treatment [17, 31, 47, 55, 57, 79, 80]. Specific features observed included increased recruitment of macrophages [21], increased angiogenesis [55, 62], and restoration of sebaceous glands and hair follicles [55].

A number of studies sought to evaluate the persistence of MSCs in the wound environment after transplantation and demonstrate that MSCs persist in the wound for up to several weeks following transplantation [17, 31, 33, 44]. Various mechanisms have been investigated to enhance cell survival following transplantation and typically involve alterations in biomimetic scaffold delivery systems [55].
3.3. Preclinical Studies. The majority of studies evaluating the role of MSCs in wound healing have been carried out in preclinical animal models. Exogenous application of MSCs during injury repair has been shown to be therapeutic in animal models. Several studies examining local injection of murine MSCs into a mouse model of incisional full thickness wound healing have consistently shown accelerated time to wound closure [21, 62, 81] with increased angiogenesis, reepithelialization, and recruitment of myeloid cells into the wound. Genetic manipulation of MSCs to overcome the hostile wound environment is emerging as a novel technique to enhance cell survival and proliferation, ultimately accelerating wound healing in animal models [82]. This is particularly important in the setting of diabetic and vascular wounds, in which local cytokine levels are inadequate to achieve normal wound healing.

Systemic delivery of adult stem cells has also been demonstrated to accelerate wound healing in cutaneous wound models. Once-daily administration of $2 \times 10^6$ cells over 4 days after wounding resulted in significantly increased wound breaking strength at days 7 and 14 [49]. In one study, MSC-treated wounds regained 52% of normal dermal tensile strength while untreated controls regained 31% of tensile strength compared to unwounded skin at 80 days following transplantation [17].

While systemic delivery of MSCs has been shown to deposit cells at the injury site, cell engraftment and survival have been limited. This has led to the majority of studies looking at novel mechanisms to locally deliver adult stem cells to enhance wound healing. Ultimately, this has generated significant collaborations between stem cell researchers and bioengineers and has resulted in the emergence of a plethora of cell delivery systems to enhance wound healing. Ideally, to identify the best strategy for cell delivery, direct comparison of various cell delivery systems is required.

3.4. Clinical Studies. Currently, there are four published clinical studies using MSC in cutaneous wound healing [24, 83–85] and a handful of single case studies [86]. Preclinical and early human trials identified in this review demonstrated that MSCs accelerated wound closure, increased tensile strength, and promoted cytokine production and angiogenesis. In 2007, Falanga et al. demonstrated accelerated healing of acute surgical wounds in human subjects ($n = 5$) when treated with BM-MSC delivered in a fibrin spray [24]. Wounds were biopsied and histology suggested that at least some MSCs migrated into the upper layers of the wound bed and differentiated into a fibroblast phenotype. Chronic venous and diabetic ulcer wounds were also examined ($n = 6$) and a significant decrease in size at 16 weeks following three topical applications of MSCs was observed.

The first randomized study in humans was produced by Dash et al. in 2009, who compared intramuscular/subcutaneous injection of BM-MSCs to standard wound care in chronic nonhealing wounds [84]. A significant decrease in ulcer size was observed in the treated group. Yoshikawa et al. introduced MSCs impregnated onto a collagen sponge topically to 20 chronic wounds and recorded complete closure in 13 cases [87]. Another case series examined 3 patients with chronic cutaneous ulcerations [83]. In this study, patients received local BM aspirate in addition to 3 additional treatments with cultured BM-MSC. All patients showed clinical improvement in their wounds within days following administration of bone marrow aspirate or cultured bone marrow cells. Wounds showed a steady overall decrease in wound size, and an increase in the vascularity of the dermis and in the dermal thickness of the wound bed was histologically suggested. No adverse events related to the delivery of bone marrow aspirate or the cultured cells were noted [83]. Arising from these early clinical studies, several trials are currently recruiting, which will examine long-term efficacy of BM-MSC therapy on diabetic and venous ulcers [73, 88, 89].

3.5. Mechanism of Action. The true mechanism of action of MSCs in accelerating wound closure is not fully understood. The current thinking is that MSCs can enhance wound healing through two main mechanisms: by providing the necessary cues for wound healing through the release of inflammatory mediators, together with key cytokines and growth factors, in addition to the cells themselves participating in the process of wound healing, ultimately differentiating into the cell types required for closure of the wound (Figure 4).

Studied carried out in vitro and in vivo studies have demonstrated that transplanted MSCs can differentiate into cells of the residing tissue, repair damaged tissue, and at least partially restore its normal function [90]. Ma et al. demonstrated in vitro differentiation of MSCs into a multilayered epidermis-like structure which expressed the epidermal markers cytokeratin-10 and filaggrin [91]. In their clinical study, Sheng et al. demonstrated recovery of sweat gland function following MSC transplantation into excision wounds in rodent skin [57]. In addition to their differentiation capacity, increasing evidence points to the ability of MSCs to secrete paracrine factors that modulate the local environment and stimulate wound healing [92]. Specifically, MSCs have been shown to significantly decrease the production of proinflammatory cytokines in the acute period when high levels can be deleterious to tissue and to upregulate them in the later regeneration phase [93]. Protein arrays have demonstrated that conditioned media from MSC cultures contain various cytokines and chemokines such as IL-8, IL-6, TGF-β, and VEGF, all of which are essential to normal wound healing [94].

MSCs have been shown to enhance wound healing through increased angiogenesis, reepithelialization, and granulation tissue formation (Figure 4). MSCs express keratinoocyte-specific markers and high levels of vascular endothelial growth factor and angiopoietin-1, suggesting that MSCs promote wound healing by differentiation and release of proangiogenic factors. Yet, other studies have demonstrated that intravenous (IV) injection in mice induced MSC transdifferentiation into keratinocytes, endothelial cells, and pericytes in cutaneous wounds. When human BM-MSCs were applied to full thickness skin defects in mice in conjunction with IV MSC administration, all wounds healed without a scar or retraction [95].
A recent hypothesis is that MSCs are pericytes, a supporting cell for blood vessels [65]. This hypothesis raises an interesting connection between these cells and angiogenesis, a key component in wound repair [65].

3.6. Safety and Regulation. Despite the rapid progress in evaluating the efficacy of MSCs in wound healing, many issues still need to be addressed. A lack of standardized isolation and delivery mechanisms for MSCs exists. Uncertainties remain as to how to best identify an ideal subpopulation of MSCs and whether freshly isolated cells are superior to cells that undergo a period of culture expansion in vitro.

All of these findings from animal transplantation studies demonstrate that MSCs can contribute to wound repair and may provide the cell source for regenerative therapy. However, further studies are necessary to extensively study not only MSCs but also the critical factors that make up the microenvironment that supports the survival and differentiation of these cells. This would allow us to determine the extent to which MSCs in the wound environment act as multipotent cells or a source of secreted factors. This research would also divide this heterogeneous cell type into more distinct and functional subpopulations.

A major obstacle to clinical translation of cellular therapies is safety and regulation of their use. Safety concerns are apparent at all stages from isolation to administration (Figure 5 details the isolation workflow). Transitioning from preclinical research in terms of in vivo models to the clinical arena represents a major step. The manipulation of MSCs for therapeutic modalities must be done in accordance with good manufacturing practices and the regulations of the FDA and/or European Medicines Agency. Other obstacles that must be addressed include the need for development of suitable serum-free media for these cells as fetal bovine serum is not recommended for clinical therapies due to the risk of contamination and infection [96].

3.7. Future Directions. Other approaches have concentrated on the delivery of MSC transfected with genes or in a suspension with plasmids or growth factors such as ectodysplasin, basic fibroblast growth factor (bFGF), or human hepatocyte growth factor [98–100]. The loss of sweat glands and thermal regulation after severe thermal injury has been a problematic area in tissue regeneration due to the multiple germ layers involved. Transplanted MSC transfected with ectodysplasin, a gene implicated in the development of sweat gland structures, into scalded paws of mice was shown to be beneficial in sweat gland regeneration [98]. Each mouse received a full thickness burn on each posterior paw and after 30 mins received a subcutaneous injection of $1 \times 10^6$ human BM-MSCs transfected with ectodysplasin. Treated animals expressed sweat gland phenotypes, cytokeratin-14, and carcinoembryonic antigen (CEA) and tested positive for perspiration [97].

As knowledge in tissue regeneration expands, researchers are exploring the synergistic effects of combining various approaches, such as augmenting cellular therapy, with other growth factors in combination with a delivery scaffold which can control the release rate of both the cells and factors into the wound [48, 50, 101].

4. Conclusion

Stem cells possess a distinct ability to self-renew and differentiate, making them a more attractive cell for cell-based therapies. Ethical concerns have limited the use of embryonic stem cells in regenerative medicine, and current focus for clinical translation lies with adult stem cells. Adult stem cells are an exciting source for wound healing applications, owing mostly to their relative ease of harvest and the ability to yield large quantities of cells. In this review, we identify that adult stem cells demonstrate huge promise in the treatment of chronic wounds. Studies evaluating the role of BM-MSCs and ASCs in treating chronic wounds demonstrate accelerated wound healing through a variety of mechanisms.

With every new scientific advancement, it is the responsibility of scientists and physicians to guide and educate the
Figure 5: Work flow of cell-based regenerative therapy. An ideal regenerative medicine strategy requires three components: an ideal cell type, biomimetic scaffold, and factors to create the desired biological response in vivo. Cutaneous wounds represent a harsh environment for cellular therapy due to their hypoxic environment and low pH which can affect the survival and potential of transplanted cells. The niche microenvironment can be manipulated with the use of scaffolds and growth factors to enhance cellular survival, promote cellular differentiation, and ultimately enhance wound healing in the clinical setting. Reproduced with permission from the authors: McArdle, Paik, Chung, Hu, and Walmsley et al. (2013) Manipulation of Stem Cells and their Microenvironment for Tissue Engineering. Surgery Curr Res 3:134.

Public on the advantages and disadvantages of any proposed therapy. Overstating potential benefits based on incomplete evidence can only serve to erode the public’s trust in the medical profession and, more concerning, compromise the safety of our patients [102]. Currently, clinical translation of adult stem cells for the treatment of chronic wounds is hindered by a lack of standardized protocols for cell characterization, isolation, and transplantation.

Areas that deserved further attention include establishing a more comprehensive understanding of the signaling network that reliably leads to robust new tissue formation, together with the identification of a definitive cell surface marker profile.

Despite the current limitations to widespread clinical use, BM-MSCs and ASCs are highly promising cell sources for the treatment of chronic wounds.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors would like to thank Sanja Trincki for graphic design. This study was supported by PRTLI-5 and the Irish Blood Transfusion Service.

References

[1] Z. N. Maan, M. Januszyn, R. C. Rennert et al., “Noncontact, low-frequency ultrasound therapy enhances neovascularization and wound healing in diabetic mice,” Plast Reconstr Surg, vol. 134, no. 3, pp. 402e–411e, 2014.

[2] J. Posnett, F. Gottrup, H. Lundgren, and G. Saal, “The resource impact of wounds on health-care providers in Europe,” J Wound Care, vol. 18, no. 4, pp. 154–161, 2009.

[3] M. S. Hu, Z. N. Maan, J. C. Wu et al., “Tissue engineering and regenerative repair in wound healing,” Annals of Biomedical Engineering, vol. 42, no. 7, pp. 1494–1507, 2014.

[4] A. J. Singer and R. A. F. Clark, “Cutaneous wound healing,” The New England Journal of Medicine, vol. 341, no. 10, pp. 738–746, 1999.

[5] N. Ilan, S. Mahooti, and J. A. Madri, “Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis,” J Cell Sci, vol. 111, part 24, pp. 3621–3631, 1998.

[6] E. McInnes, S. E. Bell-Syer, J. C. Dumville, R. Legood, and N. A. Cullum, “Support surfaces for pressure ulcer prevention,” Cochrane Database Systematic Reviews, no. 4, Article ID CD001735, 2008.

[7] S. O’Meara, N. Cullum, E. A. Nelson, and J. C. Dumville, “Compression for venous leg ulcers,” Cochrane Database Systematic Reviews, vol. 11, Article CD000265, 2012.

[8] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.

[9] A. McArdle, M. T. Chung, K. J. Paik et al., “Positive selection for bone morphogenetic protein receptor type-IB promotes differentiation and specification of human adipose-derived stromal cells toward an osteogenic lineage,” Tissue Eng Part A, vol. 20, no. 21-22, pp. 3031–3040, 2014.

[10] P. A. Zuk, M. Zhu, P. Ashjian et al., “Human adipose tissue is a source of multipotent stem cells,” Mol Biol Cell, vol. 13, no. 12, pp. 4279–4295, 2002.

[11] P. A. Zuk, M. Zhu, H. Mizuno et al., “Multilineage cells from human adipose tissue: implications for cell-based therapies,” Tissue Eng, vol. 7, no. 2, pp. 211–228, 2001.
[12] C. M. Cowan, Y.-Y. Shi, O. O. Aalami et al., “Adipose-derived adult stromal cells heal critical-size mouse calvarial defects,” *Nature Biotechnology*, vol. 22, no. 5, pp. 560–567, 2004.

[13] P. A. Zuk, “Tissue engineering craniofacial defects with adult stem cells? Are we ready yet?” *Pediatric Research*, vol. 63, no. 5, pp. 478–486, 2008.

[14] J. M. Gimble, A. J. Katz, and B. A. Bunnell, “Adipose-derived stem cells for regenerative medicine,” *Circulation Research*, vol. 100, no. 9, pp. 1249–1260, 2007.

[15] A. M. Altman, N. Matthias, Y. Yan et al., “Dermal matrix as a carrier for in vivo delivery of human adipose-derived stem cells,” *Biomaterials*, vol. 29, no. 10, pp. 1431–1442, 2008.

[16] A. M. Altman, Y. Yan, N. Matthias et al., “IFATS collection: human adipose-derived stem cells seeded on a silk fibrin-chitosan scaffold enhance wound repair in a murine soft tissue injury model,” *Stem Cells*, vol. 27, no. 1, pp. 250–258, 2009.

[17] N. M. Argòlo Neto, R. J. Del Carlo, B. S. Monteiro et al., “Role of autologous mesenchymal stem cells associated with platelet-rich plasma on healing of cutaneous wounds in diabetic mice,” *Clinical and Experimental Dermatology*, vol. 37, no. 5, pp. 544–553, 2012.

[18] M. W. Blanton, I. Hadad, B. H. Johnstone et al., “Adipose stromal cells and platelet-rich plasma therapies synergistically increase revascularization during wound healing,” *Plastic and Reconstructive Surgery*, vol. 123, no. 2, pp. 565–645, 2009.

[19] B. M. Borena, A. M. Pawde, H. P. Aithal, P. Kinjavdekar, R. Singh, and D. Kumar, “Evaluation of autologous bone marrow-derived nucleated cells for healing of full-thickness skin wounds in rabbits,” *International Wound Journal*, vol. 7, no. 4, pp. 249–260, 2010.

[20] L. Chen, E. E. Tredget, C. Liu, and Y. Wu, “Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice,” *PLoS ONE*, vol. 4, no. 9, Article ID e7119, 2009.

[21] L. Chen, E. E. Tredget, P. Y. G. Wu, and Y. Wu, “Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing,” *PLoS ONE*, vol. 3, no. 4, Article ID e1886, 2008.

[22] J.-W. Cho, M.-C. Kang, and K.-S. Lee, “TGF-ß1-treated ADSCs-CM promotes expression of type I collagen and MMP-1, migration of human skin fibroblasts, and wound healing in vitro and in vivo,” *International Journal of Molecular Medicine*, vol. 26, no. 6, pp. 901–906, 2010.

[23] T. G. Ebrahimian, F. Pouzoulet, C. Squiban et al., “Cell therapy based on adipose tissue-derived stem cells promotes physiological and pathological wound healing,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 29, no. 4, pp. 503–510, 2009.

[24] V. Falanga, S. Iwamoto, M. Chartier et al., “Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds,” *Tissue Engineering*, vol. 13, no. 6, pp. 1299–1312, 2007.

[25] X. Fu, L. Fang, H. Li, X. Li, B. Cheng, and Z. Sheng, “Adipose tissue extract enhances skin wound healing,” *Wound Repair and Regeneration*, vol. 15, no. 4, pp. 540–548, 2007.

[26] X. Fu, L. Fang, X. Li, B. Cheng, and Z. Sheng, “Enhanced wound-healing quality with bone marrow mesenchymal stem cells autografting after skin injury,” *Wound Repair and Regeneration*, vol. 14, no. 3, pp. 325–335, 2006.

[27] W. Gao, X. Qiao, S. Ma, and L. Cui, “Adipose-derived stem cells accelerate neovascularization in ischemic diabetic skin flap via expression of hypoxia-inducible factor-1α,” *Journal of Cellular and Molecular Medicine*, vol. 15, no. 12, pp. 2575–2583, 2011.

[28] J. H. Gu, J. S. Lee, D.-W. Kim, E.-S. Yoon, and E.-S. Dhong, “Neovascular potential of adipose-derived stromal cells (ASCs) from diabetic patients,” *Wound Repair and Regeneration*, vol. 20, no. 2, pp. 243–252, 2012.

[29] C. Hamou, M. J. Callaghan, H. Thangarajah et al., “Mesenchymal stem cells can participate in ischemic neovascularization,” *Plastic and Reconstructive Surgery*, vol. 123, no. 2, supplement, pp. 45S–55S, 2009.

[30] S. C. Heo, E. S. Jeon, I. H. Lee, H. S. Kim, M. B. Kim, and J. H. Kim, “Tumor necrosis factor-α-activated human adipose tissue-derived mesenchymal stem cells accelerate cutaneous wound healing through paracrine mechanisms,” *Journal of Investigative Dermatology*, vol. 131, no. 7, pp. 1559–1567, 2011.

[31] C. Hou, L. Shen, Q. Huang et al., “The effect of heme oxygenase-1 complexed with collagen on MSC performance in the treatment of diabetic ischemic ulcer,” *Biomaterials*, vol. 34, no. 1, pp. 112–120, 2013.

[32] S. Huang, G. Lu, Y. Wu et al., “Mesenchymal stem cells delivered in a microsphere-based engineered skin contribute to cutaneous wound healing and sweat gland repair,” *Journal of Dermalological Science*, vol. 66, no. 1, pp. 29–36, 2012.

[33] E. H. Javazon, S. G. Keswani, A. T. Badillo et al., “Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bone marrow stromal progenitor cells,” *Wound Repair and Regeneration*, vol. 15, no. 3, pp. 350–359, 2007.

[34] K. Kataoka, R. J. Medina, T. Kageyama et al., “Participation of adult mouse bone marrow cells in reconstitution of skin,” *American Journal of Pathology*, vol. 163, no. 4, pp. 1227–1231, 2003.

[35] C. H. Kim, J. H. Lee, J. H. Won, and M. K. Cho, “Mesenchymal stem cells improve wound healing in vivo via early activation of matrix metalloproteinase-9 and vascular endothelial growth factor,” *Journal of Korean Medical Science*, vol. 26, no. 6, pp. 726–733, 2011.

[36] W.-S. Kim, B.-S. Park, J.-H. Sung et al., “Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts,” *Journal of Dermalological Science*, vol. 48, no. 1, pp. 15–24, 2007.

[37] H. Kim, K. Choi, O.-K. Kweon, and W. H. Kim, “Enhanced wound healing effect of canine adipose-derived mesenchymal stem cells with low-level laser therapy in athymic mice,” *Journal of Dermalological Science*, vol. 68, no. 3, pp. 149–156, 2012.

[38] D. S. Kwon, X. Gao, Y. B. Liu et al., “Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats,” *International Wound Journal*, vol. 5, no. 3, pp. 453–463, 2008.

[39] S. Lee, E. Szilagyi, L. Chen et al., “Activated mesenchymal stem cells increase wound tensile strength in aged mouse model via macrophages,” *Journal of Surgical Research*, vol. 181, no. 1, pp. 20–24, 2013.

[40] E. Y. Lee, Y. Xia, W.-S. Kim et al., “Hypoxia-enhanced wound-healing function of adipose-derived stem cells: Increase in stem cell proliferation and up-regulation of VEGF and bFGF,” *Wound Repair and Regeneration*, vol. 17, no. 4, pp. 540–547, 2009.

[41] S. H. Lee, J. H. Lee, and K. H. Cho, “Effects of human adipose-derived stem cells on cutaneous wound healing in nude mice,” *Annals of Dermatogy*, vol. 23, no. 2, pp. 150–155, 2011.
Y.-C. Lin, T. Grahovac, S. J. Oh, M. Ieraci, J. P. Rubin, and S. Liu, H. Zhang, X. Zhang et al., “Synergistic angiogenesis...”

J. S. Lim and G. Yoo, “Effects of adipose-derived stromal cells and of their extract on wound healing in a mouse model,” Journal of Korean Medical Science, vol. 25, no. 5, pp. 746–751, 2010.

Y.-C. Lin, T. Grahovac, S. J. Oh, M. Ieraci, J. P. Rubin, and K. G. Marra, “Evaluation of a multi-layer adipose-derived stem cell sheet in a full-thickness wound healing model,” Acta Biomaterialia, vol. 9, no. 2, pp. 5243–5250, 2013.

P. Liu, Z. Deng, S. Han et al., “Tissue-engineered skin containing mesenchymal stem cells improves burn wounds,” Artificial Organs, vol. 32, no. 12, pp. 925–931, 2008.

S. Liu, H. Zhang, X. Zhang et al., “Synergistic angiogenesis promoting effects of extracellular matrix scaffolds and adipose-derived stem cells during wound repair,” Tissue Engineering: Part A, vol. 17, no. 5–6, pp. 725–739, 2011.

M. K. Maharloooei, M. Bagheri, Z. Solhjou et al., “Adipose tissue derived mesenchymal stem cell (AD-MSC) promotes skin wound healing in diabetic rats,” Diabetes Research and Clinical Practice, vol. 93, no. 2, pp. 228–234, 2013.

E. Mansilla, R. Spretz, G. Larsen et al., “Outstanding survival and regeneration process by the use of intelligent acellular dermal matrices and mesenchymal stem cells in a burn pig model,” Transplantation Proceedings, vol. 42, no. 10, pp. 4275–4278, 2010.

K. McFarlin, X. Gao, Y. B. Liu et al., “Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat,” Wound Repair and Regeneration, vol. 14, no. 4, pp. 471–478, 2006.

H. Nakagawa, S. Akita, M. Fukui, T. Fujii, and K. Akino, “Human mesenchymal stem cells successfully improve skin substitute wound healing,” British Journal of Dermatology, vol. 153, no. 1, pp. 29–36, 2005.

M. Nambu, S. Kishimoto, S. Nakamura et al., “Accelerated wound healing in healing-impaired db/db mice by autologous adipose tissue-derived stromal cells combined with atelocollagen matrix,” Annals of Plastic Surgery, vol. 62, no. 3, pp. 317–321, 2009.

M. Nambu, M. Ishihara, S. Nakamura et al., “Enhanced healing of mitomycin C-treated wounds in rats using inbred adipose tissue-derived stromal cells within an atelocollagen matrix,” Wound Repair and Regeneration, vol. 15, no. 4, pp. 505–510, 2007.

C. Nie, D. Yang, J. Xu, Z. Si, X. Jin, and I. Zhang, “Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis,” Cell Transplantation, vol. 20, no. 2, pp. 205–216, 2011.

M. F. Rasulov, V. T. Vasilenko, V. A. Zaidenov, and N. A. Onishchenko, “Cell transplantation inhibits inflammatory reaction and stimulates repair processes in burn wound,” Bulletin of Experimental Biology and Medicine, vol. 142, no. 1, pp. 112–115, 2006.

K. C. Rustad, V. W. Wong, M. Sorkin et al., “Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold,” Biomaterials, vol. 33, no. 1, pp. 80–90, 2012.

M. Sasaki, R. Abe, Y. Fujita, S. Ando, D. Inokuma, and H. Shimizu, “Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type,” The Journal of Immunology, vol. 180, no. 4, pp. 2581–2587, 2008.

Z. Sheng, X. Fu, S. Cai et al., “Regeneration of functional sweat gland-like structures by transplanted differentiated bone marrow mesenchymal stem cells,” Wound Repair and Regeneration, vol. 17, no. 3, pp. 427–435, 2009.

V. I. Shumakov, N. A. Onishchenko, M. F. Rasulov, M. E. Krasheninnikov, and V. A. Zaidenov, “Mesenchymal bone marrow stem cells more effectively stimulate regeneration of deep burn wounds than embryonic fibroblasts,” Bulletin of Experimental Biology and Medicine, vol. 136, no. 2, pp. 192–195, 2003.

A. Stoff, A. A. Rivera, N. S. Banerjee et al., “Promotion of incisional wound repair by human mesenchymal stem cell transplantation,” Experimental Dermatology, vol. 18, no. 4, pp. 362–369, 2009.

H. Tian, Y. Lu, S. P. Shah, and S. Hong, “14S,21R-dihydroxydocosahexaenoic acid remedies impaired healing and mesenchymal stem cell functions in diabetic wounds,” The Journal of Biological Chemistry, vol. 286, no. 6, pp. 4443–4453, 2011.

S. W. Volk, A. Radu, L. Zhang, and K. W. Liechty, “Stromal progenitor cell therapy corrects the wound-healing defect in the ischemic rabbit ear model of chronic wound repair,” Wound Repair and Regeneration, vol. 15, no. 5, pp. 736–747, 2007.

Y. Wu, L. Chen, P. G. Scott, and E. E. Tredget, “Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis,” Stem Cells, vol. 25, no. 10, pp. 2648–2659, 2007.

M. Yang, L. Sheng, H. Li, R. Weng, and Q.-F. Li, “Improvement of the skin flap survival with the bone marrow-derived mononuclear cells transplantation in a rat model,” Microsurgery, vol. 30, no. 4, pp. 275–281, 2010.

C. E. Yeum, E. Y. Park, S.-B. Lee, H.-J. Chun, and G.-T. Chae, “Quantification of MSCs involved in wound healing: use of SIS to transfer MSCs to wound site and quantification of MSCs involved in skin wound healing,” Journal of Tissue Engineering and Regenerative Medicine, vol. 7, no. 4, pp. 279–291, 2013.

S. H. Ko, A. Nauta, V. Wong, J. Glotzbach, G. C. Gurtner, and M. T. Longaker, “The role of stem cells in cutaneous wound healing: what do we really know?” Plastic and Reconstructive Surgery, vol. 127, supplement 1, pp. 105–20S, 2011.

P. Bourin, B. A. Bunnell, L. Castella et al., “Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT),” Cytotherapy, vol. 15, no. 6, pp. 641–648, 2013.

B. Levi and M. T. Longaker, “Concise review: adipose-derived stromal cells for skeletal regenerative medicine,” Stem Cells, vol. 29, no. 4, pp. 576–582, 2011.

R. D. Galiano, J. Michaels V, M. Dobryansky, J. P. Levine, and G. C. Gurtner, “Quantitative and reproducible murine model of excisional wound healing,” Wound Repair and Regeneration, vol. 12, no. 4, pp. 485–492, 2004.

J. P. Glotzbach, M. Januszzyk, I. N. Vial et al., “An information theoretic, microfluidic-based single cell analysis permits identification of subpopulations among putatively homogeneous stem cells,” PLoS ONE, vol. 6, no. 6, Article ID e21211, 2011.
[70] M. Januszky, M. Sorkin, J. P. Glotzbach et al., “Diabetes irreversibly depletes bone marrow-derived mesenchymal progenitor cell subpopulations,” Diabetes, vol. 63, no. 9, pp. 3047–3056, 2014.

[71] M. T. Chung, C. Liu, J. S. Hyun et al., “CD90 (Thy-1)-positive selection enhances osteogenic capacity of human adipose-derived stromal cells,” Tissue Engineering Part A, vol. 19, no. 7-8, pp. 989–997, 2013.

[72] E. Mansilla, V. D. Aquino, G. Roque, J. M. Tau, and A. MacEira, “Time and regeneration in burns treatment: heading into the first worldwide clinical trial with cadaveric mesenchymal stem cells,” Burns, vol. 38, no. 3, pp. 450–452, 2012.

[73] G. Dabiri, D. Heiner, and V. Falanga, “The emerging use of bone marrow-derived mesenchymal stem cells in the treatment of human chronic wounds,” Expert Opinion on Emerging Drugs, vol. 18, no. 4, pp. 405–419, 2013.

[74] V. W. Wong, K. C. Rustad, M. G. Galvez et al., “Engineered pullulan-collagen composite dermal hydrogels improve early cutaneous wound healing,” Tissue Engineering Part A, vol. 17, no. 5-6, pp. 631–644, 2011.

[75] A. J. Clover, A. H. Kumar, M. Isakson et al., “Allogeneic mesenchymal stem cells, but not culture modified monocytes, improve burn wound healing,” Burns, vol. 41, no. 3, pp. 548–557, 2015.

[76] V. W. Wong, G. C. Gurtner, and M. T. Longaker, “Wound healing: a paradigm for regeneration,” Mayo Clinic Proceedings, vol. 88, no. 9, pp. 1022–1031, 2013.

[77] A. McArdle, D. D. Lo, J. S. Hyun et al., “Discussion: a report of the ASPS task force on regenerative medicine: opportunities for plastic surgery,” Plastic and Reconstructive Surgery, vol. 131, no. 2, pp. 400–403, 2013.

[78] D. Whelan, N. M. Caplice, and A. J. Clover, “Fibrin as a delivery system in wound healing tissue engineering applications,” Journal of Controlled Release, vol. 196C, pp. 1–8, 2014.

[79] M. F. Rasulov, A. V. Vasilchenkov, N. A. Onishchenko et al., “First experience of the use bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns,” Bulletin of Experimental Biology and Medicine, vol. 139, no. 1, pp. 141–144, 2005.

[80] M. Nambu, S. Kishimoto, S. Nakamura et al., “Accelerated wound healing in healing-impaired db/db mice by autologous adipose tissue-derived stromal cells combined with atelocollagen matrix,” Annals of Plastic Surgery, vol. 62, no. 3, pp. 317–321, 2009.

[81] M. Sasaki, R. Abe, Y. Fujita, S. Ando, D. Inokuma, and H. Shimizu, “Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type,” Journal of Immunology, vol. 180, no. 4, pp. 2581–2587, 2008.

[82] A. Nauta, C. Seidel, L. Deveza et al., “Adipose-derived stromal cells overexpressing vascular endothelial growth factor accelerate mouse excisional wound healing,” Molecular Therapy, vol. 21, no. 2, pp. 445–455, 2013.

[83] E. V. Badiavas and V. Falanga, “Treatment of chronic wounds with bone marrow-derived cells,” Archives of Dermatology, vol. 139, no. 4, pp. 510–516, 2003.

[84] N. R. Dash, S. N. Dash, P. Routray, S. Mohapatra, and P. C. Mohapatra, “Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells,” Rejuvenation Research, vol. 12, no. 5, pp. 359–366, 2009.

[85] T. Yoshikawa, H. Mitsuno, I. Nonaka et al., “Wound therapy by marrow mesenchymal cell transplantation,” Plastic and Reconstructive Surgery, vol. 121, no. 3, pp. 860–877, 2008.

[86] M. F. Rasulov, V. I. Sevast’ianov, V. A. Egorova et al., “A comparative study of the dynamics of deep burns healing in using medullary allogenic fibroblast-like mesenchymal stem cells from bone marrow immobilized on biodegrading membranes or taken from cultural plastic,” Patologicheskaia Fiziologiya i Eksperimental’naia Terapiiia, no. 2, pp. 20–23, 2005.

[87] T. Yoshikawa, H. Mitsuno, I. Nonaka et al., “Wound therapy by marrow mesenchymal cell transplantation,” Plastic and Reconstructive Surgery, vol. 121, no. 3, pp. 860–877, 2008.

[88] I. Siev-Ner, Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers, 2012, http://clinicaltrials.gov/ct2/show/NCT01686139.

[89] V. Falanga, Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds, 2012, http://clinicaltrials.gov/ct2/show/NCT01751282.

[90] D. Baksh, L. Song, and R. S. Tuan, “Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy,” Journal of Cellular and Molecular Medicine, vol. 8, no. 3, pp. 301–316, 2004.

[91] K. Ma, F. Laco, S. Ramakrishna, S. Liao, and C. K. Chan, “Differentiation of bone marrow-derived mesenchymal stem cells into multi-layered epidermis-like cells in 3D organotypic coculture,” Biomaterials, vol. 30, no. 19, pp. 3251–3258, 2009.

[92] H. H. Li and X. Fu, “Mechanisms of action of mesenchymal stem cells in cutaneous wound repair and regeneration,” Cell and Tissue Research, vol. 348, no. 3, pp. 371–377, 2012.

[93] L. T. Galindo, T. R. M. Filippo, S. Patricia et al., “Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury,” Neurology Research International, vol. 2011, Article ID 564089, 9 pages, 2011.

[94] B. S. Yoon, J.-H. Moon, E. K. Jun et al., “Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells,” Stem Cells and Development, vol. 19, no. 6, pp. 887–902, 2010.

[95] E. Mansilla, G. H. Marin, F. Sturla et al., “Human mesenchymal stem cells are tolerized by mice and improve skin and spinal cord injuries,” Transplantation Proceedings, vol. 37, no. 1, pp. 292–294, 2005.

[96] K. Senarath-Yapa, A. McArdle, A. Renda, M. T. Longaker, and N. Quarto, “Adipose-derived stem cells: characterization, differentiation, and application in cell and gene therapy,” Expert Opinion on Investigational Drugs, vol. 12, no. 5, pp. 359–364, 2003.

[97] K. Senarath-Yapa, A. McArdle, A. Renda, M. T. Longaker, and N. Quarto, “Adipose-derived stem cells transfected with ectodysplasin for regeneration,” Transplantation Proceedings, vol. 37, no. 1, pp. 292–294, 2005.

[98] K. Senarath-Yapa, A. McArdle, A. Renda, M. T. Longaker, and N. Quarto, “Adipose-derived stem cells: a review of signaling networks governing cell fate and regenerative potential in the context of craniofacial and long bone skeletal repair,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9314–9330, 2014.

[99] S. Cai, Y. Pan, B. Han, T.-Z. Sun, Z.-Y. Sheng, and X.-B. Fu, “Transplantation of human bone marrow-derived mesenchymal stem cells transfected with ectodysplasin for regeneration of sweat glands,” Chinese Medical Journal, vol. 124, no. 15, pp. 2260–2268, 2011.

[100] X.-B. Fu, L.-J. Fang, Y.-X. Wang, T.-Z. Sun, and B. Cheng, “Enhancing the repair quality of skin injury on porcine after autografting with the bone marrow mesenchymal stem cells,” Zhonghua Yi Xue Za Zhi, vol. 84, no. 11, pp. 920–924, 2004.

[101] C. Zhang, X.-Q. Ha, Y. Liu, L.-J. Jin, and T.-D. Lü, “Bone marrow mesenchymal stem cells transfected with hepatocyte growth factor gene for repair of burn wound after allotransplantation,” Journal of Clinical Rehbitative Tissue Engineering Research, vol. 12, no. 51, pp. 10134–10138, 2008.
[100] Z. Sheng, X. Fu, S. Cai et al., “Regeneration of functional sweat gland-like structures by transplanted differentiated bone marrow mesenchymal stem cells,” _Wound Repair and Regeneration_, vol. 17, no. 3, pp. 427–435, 2009.

[101] H. Liu, X.-Q. Li, W.-P. Chen, H.-X. Xiang, J. Hu, and X.-W. Zhang, “Construction of tissue engineered skin by collagen with bone mesenchymal stem cells transfected with angiotensin I for repairing wound surface in scald models,” _Journal of Clinical Rehabilitative Tissue Engineering Research_, vol. 13, no. 15, pp. 2859–2864, 2009.

[102] A. Mc Ardle, K. Senarath-Yapa, G. G. Walmsley et al., “The role of stem cells in aesthetic surgery: fact or fiction?” _Plastic and Reconstructive Surgery_, vol. 134, no. 2, pp. 193–200, 2014.